Literature DB >> 7802704

Purine substrates for human thiopurine methyltransferase.

M Deininger1, C L Szumlanski, D M Otterness, J Van Loon, W Ferber, R M Weinshilboum.   

Abstract

Thiopurine methyltransferase (TPMT) catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG). A genetic polymorphism regulating TPMT activity in human tissue is an important factor responsible for individual differences in the toxicity and therapeutic efficacy of these drugs. Because of the clinical importance of this polymorphism, we studied 18 purine derivatives, including ribonucleosides and ribonucleotides, as potential substrates for purified human kidney TPMT. Sixteen of the compounds studied were substrates for the enzyme, with Km values that varied from 29.1 to 1270 microM and with Vmax values that varied from 75 to 2340 U/mg protein. The thiopurines tested had Km values that were uniformly lower than were those of the corresponding ribonucleosides or ribonucleotides. 6-Selenopurine derivatives had the lowest Km values of the compounds studied. Finally, oxidized purines with an OH in the 8-position were methylated by the enzyme, but 2-OH compounds were potent inhibitors of TPMT.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7802704     DOI: 10.1016/0006-2952(94)90515-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

Review 1.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

Review 2.  Pharmacogenetics: a tool for individualizing antineoplastic therapy.

Authors:  F Innocenti; L Iyer; M J Ratain
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

3.  Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity.

Authors:  D M Otterness; C L Szumlanski; T C Wood; R M Weinshilboum
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

4.  Human thiopurine methyltransferase activity varies with red blood cell age.

Authors:  L Lennard; T S Chew; J S Lilleyman
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

5.  6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations.

Authors:  D L Lancaster; N Patel; L Lennard; J S Lilleyman
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

6.  Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide.

Authors:  R A Lysaa; T Giverhaug; H L Wold; J Aarbakke
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

7.  Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.

Authors:  Ahmed F Hawwa; Jeff S Millership; Paul S Collier; Koen Vandenbroeck; Anthony McCarthy; Sid Dempsey; Carole Cairns; John Collins; Colin Rodgers; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

8.  Implementation of TPMT testing.

Authors:  Lynne Lennard
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

9.  The development of an objective methodology to measure medication adherence to oral thiopurines in paediatric patients with acute lymphoblastic leukaemia--an exploratory study.

Authors:  Ahmed F Hawwa; Jeff S Millership; Paul S Collier; Anthony McCarthy; Sid Dempsey; Carole Cairns; James C McElnay
Journal:  Eur J Clin Pharmacol       Date:  2009-07-28       Impact factor: 2.953

10.  TPMT in the treatment of Crohn's disease with azathioprine.

Authors:  L Lennard
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.